Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intralipid Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Mechanisms in Obesity

NCT05553405
View directory record Official record
Conditions
Obesity
Interventions
Intralipid Infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2033
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA-Induced Hypertension and Endothelial Dysfunction

NCT00589888
View directory record Official record
Conditions
Endothelial Dysfunction, Hypertension
Interventions
Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

NCT02185729
View directory record Official record
Conditions
Diseases, Metabolic, Insulin Sensitivity
Interventions
Intralipid, ClinOleic, Dextrose, Saline (control)
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation

NCT02512718
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Omegaven, Soybean oil lipid emulsion
Drug
Lead sponsor
Alexandra N. Carey
Other
Eligibility
2 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
View directory record Official record
Conditions
Healthy, Type 2 Diabetes
Interventions
Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
Biological
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 2, 2026, 12:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

NCT04584983
View directory record Official record
Conditions
Bilirubin Encephalopathy
Interventions
usual prescribed intralipid (UL) regimen, restricted prescribed intralipid (RL) regimen
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 27 Weeks
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 2, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NCT00088647
View directory record Official record
Conditions
Neoplasms
Interventions
MST-997
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2006 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Early Phase 1 Interventional

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy

NCT01306838
View directory record Official record
Conditions
Short Bowel Syndrome, Necrotizing Enterocolitis, Small Intestine Perforation
Interventions
MicroLipid and fish oil, Routine care
Dietary Supplement · Other
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling

NCT01740817
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Intralipid 20%, Saline
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 3 Interventional

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

NCT00111189
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Paliperidone Palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
18
States / cities
Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 2, 2026, 12:14 AM EDT
Withdrawn Phase 3 Interventional

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

NCT04592380
View directory record Official record
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns

NCT03857646
View directory record Official record
Conditions
Prematurity
Interventions
Intralipid, 20% Intravenous Emulsion, Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Days to 8 Days
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01089426
View directory record Official record
Conditions
Liver Injury
Interventions
Omegaven™, Historical Controls
Drug · Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 2, 2026, 12:14 AM EDT
Terminated Not applicable Interventional

Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic

NCT00278928
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Liposyn III 20% (lipid infusion), Intralipid 20% (lipid infusion)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
2 Days to 10 Days
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 2, 2026, 12:14 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Reprometabolic Syndrome Mediates Subfertility in Obesity

NCT02653092
View directory record Official record
Conditions
Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions
Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 2, 2026, 12:14 AM EDT
Withdrawn Not applicable Interventional

Compassionate Use of Omegaven IV Fat Emulsion

NCT01323907
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Sivan Kinberg
Other
Eligibility
2 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis

NCT01555957
View directory record Official record
Conditions
Parenteral Nutrition Associated Cholestasis
Interventions
intravenous lipid
Drug
Lead sponsor
University of Rochester
Other
Eligibility
Up to 72 Hours
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 2, 2026, 12:14 AM EDT
Withdrawn Phase 4 Interventional

SMOFLipid in Patients Who Are Intralipid Intolerant

NCT03054948
View directory record Official record
Conditions
Home Parenteral Nutrition, Short Bowel Syndrome
Interventions
SMOFLipid, Standard therapy
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 2, 2026, 12:14 AM EDT
Not listed Not applicable Interventional

Omegaven® as Parenteral Nutrition

NCT02334293
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Carle Foundation Hospital
Other
Eligibility
14 Days to 4 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT05614544
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, Propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Not applicable Interventional

Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

NCT00002029
View directory record Official record
Conditions
HIV Infections
Interventions
Fat Emulsion 2%, Fat Emulsion 20%
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Miami, Florida • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Sep 2, 2026, 12:14 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

NCT02929303
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

NCT00826020
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions
Omegaven™
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 2, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 2, 2026, 12:14 AM EDT